Needham analyst Alan Carr was out today with a favorable report on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after meeting with management for a corporate update and hosting a series of meetings with investors.
ACADIA Pharmaceuticals Inc. (ACAD) ended last trading session with a change of 4.07 percent. It trades at an average volume of 2.61M shares versus 3.16M shares recorded at the end of last trading session.
Zacks uses a rating methodology that is presented in a simple sliding scale of 1 to 5. In that scale, 3 represents HOLD rating while the numbers that fall on the left hand-side of 3 (1 and 2) indicate a BUY recommendation.
Acadia Pharmaceuticals Inc. (ACAD) has been the model of inconsistency and unpredictability over the last year. Acadia Pharmaceuticals Inc.: Why ACAD Stock Will Be Volatile Over The Next Year ACAD is currently trading right in the middle of its 52-week ...